Metastatic Colorectal Cancer (mCRC) Archives

News Brief: Merck, Eisai, Sherlock, Bill & Melinda Gates Foundation and More

Adeno-Associated Virus (AAV), Biopharma, Calcitonin Gene-Related Peptide (CGRP) Inhibitors, CCR5 antagonists, Clinical Trials, Data, Endometrial Cancer, GLB1 gene, Hospitalized COVID-19 Patients, Metastatic Colorectal Cancer (mCRC), Overall Response Rate (ORR), R&D, The Bill and Melinda Gates Foundation, The Lancet, Tyrosine kinase inhibitors, United Kingdom

A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.

December 16, 2020/by Andrew Humphreys

Celyad’s High Hopes for a Path Forward in Cancer Immunotherapy with CYAD-211

B-cell maturation antigen (BCMA), Biotechnology, CAR-T Therapy, Cell Therapy, Clinical Trials, Gene Editing, Immunotherapies, Metastatic Colorectal Cancer (mCRC), Oncology, R&D, Relapse/Refractory Multiple Myeloma

Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.

September 2, 2020/by BioSpace

Merck’s Keytruda Hits Coprimary Endpoint Early in Colorectal Cancer Trial

Blockbusters, Checkpoint Inhibitors, Chemotherapy, Clinical Trials, Colorectal Cancer, Data Monitoring Committee (DMC), Metastatic Colorectal Cancer (mCRC), Overall Survival (OS), Primary Endpoints, Progression-Free Survival (PFS), R&D, Therapeutics

Merck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.

April 2, 2020/by BioSpace